3 New Strong Buy Ratings from Top-Rated Analysts: 04/09/2026
Oh happy day. Here are three fresh Strong Buy ratings to check out:
- AbbVie Inc (ABBV) — Dividend aristocrat with expanding oncology firepower
- Teva Pharmaceutical Industries Ltd (TEVA) — Turnaround play surging 139% with biosimilar momentum
- Calix Inc ($CALX) — AI-powered broadband disruptor with 580% earnings growth
P.S. Get more alerts like this daily … Try WallStreetZen Premium.
A note from our sponsors...
Buffett's $114 Secret In 1943, a teenage Warren Buffett put $114 into a special type of account called "The 29% Account." Today, that single, $114 investment would be worth over $15 million. Your bank never told you about this. Click Here to See How It Works1. Abbvie Inc (NYSE: ABBV)
AbbVie has a problem most companies would envy: replacing a blockbuster drug like Humira — and actually pulling it off. With an expanding oncology lineup, rock-solid dividends, and a strong 2026 forecast, the 3-ranked drug manufacturer is giving investors plenty of reasons to pay attention.
Zen Rating: B (Buy) — see full analysis
Recent Price: $207.70 — get current quote
Max 1-year forecast: $299.00
Why we're watching:
- Analyst support: Right now, 14 analysts we track issue ratings on ABBV. It earns 8 Strong Buy ratings, 3 Buy ratings, and 3 Hold ratings, demonstrating solid conviction despite macro uncertainties. See the ratings
- For instance, Piper Sandler's David Amsellem (a top 7% rated analyst) maintains a Strong Buy rating with a $299.00 price target (over 40% upside), remarking on AbbVie's strong fundamentals and growth trajectory, especially in immunology.
- Industry ranking context: ABBV is currently the 5th highest-rated stock in the General Drug Manufacturer industry, which has an Industry Rating of A, positioning it among pharmaceutical elite. See more stocks in the industry here.
- Zen Rating highlights: Right now, ABBV ranks in the top 17% of 4,600+ stocks we track and earns an overall grade of B (Buy), which is above average.
- Component Grades: The company shows specific strength in Safety, Growth and Financials — it earns above-average B Component Grades in each of these areas. See all 7 Zen Component Grades here.
2. Teva Pharmaceutical Industries (NYSE: TEVA)
Teva Pharmaceutical Industries is in the middle of a multi-year transformation — and it's starting to pay off. The 3-ranked pharmaceutical company just scored FDA approval for its Prolia biosimilar PONLIMSI™, with a Xolair filing acceptance signaling even more growth ahead as Teva pivots toward higher-value products.
Zen Rating: A (Strong Buy) — see full analysis
Recent Price: $29.90 — get current quote
Max 1-year forecast: $45.00
Why we're watching:
- Analyst support: TEVA enjoys exceptional Wall Street confidence with 6 Strong Buy ratings and 1 Buy rating out of 7 total analysts, with no Hold or Sell recommendations. See the ratings
- For instance, Piper Sandler's David Amsellem (a top 7% rated analyst) reiterated a Strong Buy rating with a $41.00 price target (suggesting nearly 40% upside) in early March, maintaining conviction in the turnaround story.
- Industry ranking context: TEVA is currently the 3rd highest-rated stock in the Pharmaceutical industry, which has an Industry Rating of B, placing it among top-tier drug manufacturers.
- Zen Rating highlights: Strong Buy (A) stocks average +32.52%/yr — TEVA is part of this elite tier of the top-rated stocks we track in our 4600+ ticker database.
- Component Grades: The company earns B grades across Value, Growth, Momentum, Safety, and artificial intelligence integration, reflecting balanced strength across multiple dimensions. See all 7 Zen Component Grades here
3. Calix Inc (NYSE: CALX)
Calix Inc is quietly becoming the AI backbone of America's broadband buildout. The #7-ranked app company just launched its AI-native Calix One platform and landed one of the nation's largest BEAD-funded fiber deployments, with up to $1.5 billion in BEAD opportunity ahead and agentic AI solutions already driving record revenue past the $1 billion mark.
Zen Rating: A (Strong Buy) — see full analysis
Recent Price: $49.95 — get current quote
Max 1-year forecast: $90.00
Why we're watching:
- Analyst support: CALX enjoys 2 Strong Buy ratings and 1 Buy rating out of 3 total analysts — as an added bonus, all three analysts are ranked in the top 1% based on stock-picking performance. See the ratings
- For example, JP Morgan's Samik Chatterjee (a top 1% rated analyst) upgraded CALX to Strong Buy with a $90.00 price target in January 2026, representing a remarkable +86% upside potential from current levels.
- Needham analyst Ryan Koontz (top 1%) maintains a Buy rating with a $70.00 target, noting that while Q1 2026 guidance was mixed due to seasonal winter fiber passing declines, the new agentic workforce cloud platform has "very strong potential" to "revolutionize customers' businesses."
- Industry ranking context: CALX is currently the 7th highest-rated stock in the App industry, which has an Industry Rating of B, positioning it strongly among software and platform providers.
- Zen Rating highlights: CALX earns an overall A (Strong Buy) Zen Rating. This rating is only given to the top 5% of stocks we track based on a detailed 115-factor analysis, and stocks that earn this rating have historically gained over 30% annually.
- Component Grades: The company earns an A in Growth and a B in Financials, while holding C grades in Value, Momentum, Sentiment, Safety, and Artificial Intelligence — reflecting solid growth execution as it scales its AI-native broadband platform. See all 7 Zen Component Grades here
What to Do Next?
Want to get in touch? Email us at news@wallstreetzen.com.
Keep Reading
See All News
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.